1152617-24-7

Basic information

• Product Name: (3-Chloro-4-iodopyridin-2-yl)amine
• Synonyms: (3-Chloro-4-iodopyridin-2-yl)amine;3-Chloro-4-iodo-2-pyridinamine;3-Chloro-4-Iodopyridin-2-Amine
• CAS NO: 1152617-24-7
• Molecular Formula: C₅H₄ClIN₂
• Molecular Weight: 254.45613
• Mol File: 1152617-24-7.mol

Chemical Properties

• Boiling Point: 308.9±42.0 °C(Predicted)
• Appearance: /
• Density: 2.139±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 3.25±0.47(Predicted)
• CAS DataBase Reference: (3-Chloro-4-iodopyridin-2-yl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Chloro-4-iodopyridin-2-yl)amine(1152617-24-7)
• EPA Substance Registry System: (3-Chloro-4-iodopyridin-2-yl)amine(1152617-24-7)

Safety Data

• Hazardous Substances Data: 1152617-24-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(3-Chloro-4-iodopyridin-2-yl)amine is used as a key intermediate in the development of pharmaceuticals for its ability to contribute to the creation of diverse medicinal compounds with potential therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, (3-Chloro-4-iodopyridin-2-yl)amine is employed as a building block for the synthesis of various agrochemicals, contributing to the development of effective crop protection agents and other agricultural products.
Used in Specialty Chemicals Synthesis:
(3-Chloro-4-iodopyridin-2-yl)amine is utilized as a versatile intermediate in the synthesis of specialty chemicals, where its unique structure and functional groups allow for the creation of compounds with specific applications in various industries.
Used in Material Development:
(3-Chloro-4-iodopyridin-2-yl)amine is also used in the development of new materials, leveraging its structural and functional attributes to enhance or create properties in materials for different applications.
Used as a Reagent in Organic Synthesis:
(3-Chloro-4-iodopyridin-2-yl)amine serves as a reagent in organic synthesis, where it is used to introduce the pyridine ring and amine group into target molecules, facilitating the synthesis of complex organic compounds for research and industrial applications.

Upstream product

• 796851-05-3 3-chloro-2-fluoro-4-iodopyridine 
• 1480-64-4 3-chloro-2-fluoropyridine 
• 889865-45-6 2,3-dichloro-4-iodopyridine 
• 2402-77-9 2,3-dichloro-pyridine 

Downstream Products

• 1414370-77-6 8-chloro-7-(4-fluorophenyl)-2-methylimidazo[1,2-a]pyridine 
• 1416551-60-4 8-chloro-7-iodo-2-methylimidazo[1,2-a]pyridine 
• 1414371-25-7 8-chloro-7-iodo-2-phenylimidazo[1,2-a]pyridine 
• 1414371-13-3 ethyl 7-(cyclohexylamino)-8-(pyridin-4-yl)imidazo[1,2-a]pyridine-2-carboxylate 
• 1414371-08-6 2-phenyl-8-(pyridin-4-yl)imidazo[1,2-a]pyridine-7-carbonitrile 
• 1414371-07-5 2-phenyl-8-(thien-3-yl)imidazo[1,2-a]pyridine-7-carbonitrile 
• 1414371-06-4 8-(fur-2-yl)-7-(p-tolylethynyl)-2-phenylimidazo[1,2-a]pyridine 
• 1414371-05-3 7-(4-fluorophenyl)-2-methyl-8-(pyridin-4-yl)imidazo[1,2-a]pyridine 
• 1414370-91-4 ethyl 8-chloro-7-(cyclohexylamino)imidazo[1,2-a]pyridine-2-carboxylate 
• 1414370-90-3 N-(8-chloro-2-phenylimidazo[1,2-a]pyridin-7-yl)aniline 
• 1414370-84-5 8-chloro-2-phenylimidazo[1,2-a]pyridine-7-carbonitrile 
• 1414370-79-8 ethyl 8-chloro-7-(p-tolylethynyl)imidazo[1,2-a]pyridine-2-carboxylate 
• 1414370-78-7 8-chloro-7-(p-tolylethynyl)-2-phenylimidazo[1,2-a]pyridine 
• 1414370-76-5 ethyl 8-chloro-7-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxylate 

Relevant articles and documents

MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING ACTIVITY OF SHP2

Provided herein is a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme, wherein LG, A, n, m and p are as defined in the Summary of the Invention, said manufacture including the manufacture and use of a compound of the formula VI, wherein R1 is a secondary amino protecting group and R5 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted aryl.

Aryl spiro compound containing formamidine as well as preparation method and application of aryl spiro compound

The invention belongs to the field of medicinal chemistry, and particularly relates to an aryl spiro compound containing formamidine as well as a preparation method and application of the aryl spiro compound. The invention relates to three aryl spiro compounds as shown in general formulas I-III and pharmaceutically acceptable salts, enantiomers, non-isomers, tautomers, solvates, polymorphic substances or prodrugs thereof. On the basis that SHP099 is used as a lead compound, a brand new compound with guanidyl at the tail end is prepared, and the problems that an existing SHP2 inhibitor is single in structural framework and the like are solved. The aryl spiro compound has the important significance of providing many modification sites and providing a basis for later structural modification. Meanwhile, the embodiment of the invention proves that the compound has an allosteric inhibition effect on SHP2 phosphatase, and a skeleton support is provided for subsequent development of an SHP2 phosphatase inhibitor.

MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2

The present invention relates to a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein LG, A, n, m and p are as defined in the Summary of the Invention.

PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2

The invention relates to a method for the manufacture of a compound of Formula I as mentioned above, or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II wit

Pyrazinothiazole compound and application thereof, and pharmaceutical composition containing pyrazinothiazole compound

The invention discloses a pyrazinothiazole compound, an application of the pyrazinothiazole compound, and a pharmaceutical composition containing the pyrazinothiazole compound, and provides a pyrazinothiazole compound represented by a formula A or a pharmaceutically acceptable salt of the pyrazinothiazole compound. The pyrazinothiazole compound provided by the invention has relatively good SHP2 inhibitory activity.

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.

FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS

This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.

Synthesis and evaluation of the anticoccidial activity of trifluoropyrido[1,2-a]pyrimidin-2-one derivatives

Screening of our chemical library to discover new molecules exhibiting in vitro activity against the invasion of host cells by Eimeria tenella revealed a lead compound with an IC50 of 15 μM. Structure-activity relationship studies were conducted with 34 newly synthesized compounds to identify more active molecules and enhance in vitro activity against the parasite. Four compounds were more effective in inhibiting MDBK cell invasion in vitro than the lead compound.

Imidazo[1,2-a]pyridines: Orally active positive allosteric modulators of the metabotropic glutamate 2 receptor

Advanced leads of an imidazopyridine series of positive allosteric modulators of the metabotropic glutamate 2 (mGlu2) receptor are reported. The optimization of in vitro ADMET and in vivo pharmacokinetic properties led to the identification of 27o. With g